News

AbbVie (NYSE:ABBV) shared new real-world and pediatric safety data for VRAYLAR in MDD and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups. Pediatric data for VRAYLAR added information on safety and use in younger patients with mood disorders. The fresh VRAYLAR real-world and pediatric results sit against a wider backdrop our research has uncovered. Check out 4 warning signs that...

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.

AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, 2026, to shareholders of record as of October 15. There is no new increase this time, since AbbVie has kept its quarterly dividend at $1.73 throughout 2026. Still, the latest declaration confirms the higher payout […]

A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.

The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.

Key Stats for AbbVie StockCurrent Price: $263. 04Target Price (Mid): ~$361Street Target: ~$279Potential Total Return: ~37% (over ~4.

AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.

AbbVie has delivered a powerful run over the past several years, and the current share price of US$262.51 reflects significant confidence in its ability to keep turning today’s drug portfolio and pipeline into future cash. The open question for you as an investor is whether those cash flows, when you project and discount them, line up with where the stock now trades. AbbVie has returned 196.4% over the past 5 years, which raises the stakes on whether its future cash generation fully supports...

Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.

Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.

ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.

AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.

SCHD's 0.06% expense ratio gets all the attention, but something that happened quietly in March may have cost dividend investors far more than a decade of fees combined.

Two portfolios generating identical dividend income can leave one investor thousands of dollars richer than the other, and the difference has nothing to do with yield. The culprit is hiding inside your 1099-DIV.

Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.

AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles. The treatment […]

A Roth IRA turns every dividend into a tax shield: qualified distributions in retirement escape federal income tax entirely, and reinvested payouts compound without a drag from Uncle Sam. That advantage is especially potent for REIT distributions, which are typically taxed as ordinary income in a taxable account. The five blue chips below combine long […]

Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.

Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.

AbbVie's dividend is a very appealing factor.

AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.

LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.

ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.

There are currently no targeted therapies specifically approved for menstrual migraine, though other anti-migraine drugs are used off-label in this indication.